Should I buy or sell Exagen stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XGN shares. View XGN analyst ratings or view top-rated stocks .

What is Exagen's stock price target for 2024?

2 brokers have issued twelve-month price objectives for Exagen's shares. Their XGN share price targets range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 338.0% from the stock's current price. View analysts price targets for XGN or view top-rated stocks among Wall Street analysts .

How have XGN shares performed in 2024?

Exagen's stock was trading at $1.99 at the beginning of 2024. Since then, XGN shares have decreased by 31.2% and is now trading at $1.37. View the best growth stocks for 2024 here .

Are investors shorting Exagen?

Exagen saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 20,500 shares, an increase of 294.2% from the March 15th total of 5,200 shares. Based on an average daily volume of 43,900 shares, the short-interest ratio is currently 0.5 days. Currently, 0.3% of the shares of the company are short sold. View Exagen's Short Interest .

When is Exagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our XGN earnings forecast .

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) announced its earnings results on Monday, March, 18th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.02. The business earned $13.77 million during the quarter, compared to the consensus estimate of $11.43 million. Exagen had a negative trailing twelve-month return on equity of 80.28% and a negative net margin of 45.08%. During the same quarter last year, the business earned ($0.58) earnings per share.

What guidance has Exagen issued on next quarter's earnings?

Exagen issued an update on its FY 2024 earnings guidance on Monday, March, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.0 million-$54.0 million, compared to the consensus revenue estimate of $54.1 million.

What is Ron Rocca's approval rating as Exagen's CEO?

5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com . Ron Rocca has an approval rating of 80% among the company's employees.

Exagen (XGN) raised $50 million in an initial public offering (IPO) on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

Who are Exagen's major shareholders?

Exagen's stock is owned by a number of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (4.56%). Insiders that own company stock include James L L Tullis , John Aballi, Kamal Adawi, Mark Hazeltine and Wendy S Johnson . View institutional ownership trends .

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:XGN

Exagen (XGN) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free XGN Stock Alerts

$1.37

-0.06 (-4.20%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.35
▼
$1.43
50-Day Range: $1.40
▼
$2.25
52-Week Range: $1.30
▼
$3.92

Volume: 6,591 shs
Average Volume: 40,316 shs
Market Capitalization: $23.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Get Exagen alerts:

Exagen MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 338.0% Upside
$6.00 Price Target
Short Interest: Healthy
0.26% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.29
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$24,417 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.46) to ($1.03) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.11 out of 5 stars

Medical Sector

155th out of 911 stocks

Medical Laboratories Industry

5th out of 20 stocks

3.5

Analyst's Opinion

Consensus Rating
Exagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Exagen has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.26% of the float of Exagen has been sold short.
Short Interest Ratio / Days to Cover
Exagen has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Exagen has recently increased by 294.23%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Exagen does not currently pay a dividend.
Dividend Growth
Exagen does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Exagen has received a 70.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Immunology laboratory services for research" products. See details.
Environmental Sustainability
The Environmental Impact score for Exagen is -1.29.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Exagen this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Exagen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,417.00 in company stock.
Percentage Held by Insiders
36.80% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Exagen are expected to grow in the coming year, from ($1.46) to ($1.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exagen is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exagen is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Exagen has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Exagen Stock (NASDAQ:XGN)

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

XGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XGN Stock News Headlines

April 16, 2024 | morningstar.com

Exagen Inc Ordinary Shares

April 11, 2024 | americanbankingnews.com

Short Interest in Exagen Inc. (NASDAQ:XGN) Increases By 294.2%

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 21, 2024 | finance.yahoo.com

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual Report

March 20, 2024 | seekingalpha.com

Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript

March 20, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives

March 20, 2024 | finance.yahoo.com

Exagen Full Year 2023 Earnings: Beats Expectations

March 19, 2024 | finance.yahoo.com

Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 19, 2024 | markets.businessinsider.com

Exagen’s Strong Q4 Performance and Positive Outlook Justify Buy Rating

March 18, 2024 | markets.businessinsider.com

Here's what to expect from Exagen's earnings

March 18, 2024 | msn.com

Exagen reports Q4 results

March 18, 2024 | investorplace.com

XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023

March 18, 2024 | msn.com

Anticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See Upticks

March 18, 2024 | globenewswire.com

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

March 18, 2024 | finance.yahoo.com

XGN Apr 2024 2.500 put

March 8, 2024 | finance.yahoo.com

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

March 8, 2024 | globenewswire.com

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

March 7, 2024 | globenewswire.com

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

February 6, 2024 | finance.yahoo.com

Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock

January 30, 2024 | finance.yahoo.com

Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 8, 2024 | msn.com

Exagen reaffirms FY23 revenue of at least $50M

January 7, 2024 | finance.yahoo.com

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

December 30, 2023 | benzinga.com

Exagen Stock (NASDAQ:XGN) Dividends: History, Yield and Dates

December 20, 2023 | msn.com

Exagen submits plans for new solar farm in Wiltshire

November 17, 2023 | msn.com

Exagen files for a $150M mixed shelf offering

November 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Milestone Pharmaceuticals (MIST)

See More Headlines

Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:XGN
CUSIP: N/A
CIK: 1274737
Web: www.exagen.com
Phone: 760-560-1501
Fax: N/A
Employees: 174
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $6.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +327.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,690,000.00
Net Margins: -45.08%
Pretax Margin: -45.02%
Return on Equity: -80.28%
Return on Assets: -36.27%

Debt

Debt-to-Equity Ratio: 0.85
Current Ratio: 4.02
Quick Ratio: 4.02

Sales & Book Value

Annual Sales: $52.55 million
Price / Sales: 0.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.33 per share
Price / Book: 1.06

Miscellaneous

Outstanding Shares: 17,240,000
Free Float: 10,893,000
Market Cap: $24.22 million
Optionable: Optionable
Beta: 1.19

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Tina S. Nova Ph.D. (Age 70)
Executive Chairman of the Board of Directors
Comp: $65k
Mr. John Aballi (Age 39)
CEO, President & Director
Comp: $558.84k
Mr. Kamal Adawi M.S. (Age 45)
MBA, CFO & Corporate Secretary
Comp: $483.28k
Ryan Douglas
Investors Relations Officer
Mr. John Wegener (Age 55)
Senior Vice President of Sales and Marketing
Dr. Andrew L. Concoff FACR
M.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
Dr. Michael I. Nerenberg M.D. (Age 69)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Exagen stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XGN shares.
View XGN analyst ratings or view top-rated stocks.
What is Exagen's stock price target for 2024?: 2 brokers have issued twelve-month price objectives for Exagen's shares. Their XGN share price targets range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 338.0% from the stock's current price.
View analysts price targets for XGN or view top-rated stocks among Wall Street analysts.
How have XGN shares performed in 2024?: Exagen's stock was trading at $1.99 at the beginning of 2024. Since then, XGN shares have decreased by 31.2% and is now trading at $1.37.
View the best growth stocks for 2024 here.
Are investors shorting Exagen?: Exagen saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 20,500 shares, an increase of 294.2% from the March 15th total of 5,200 shares. Based on an average daily volume of 43,900 shares, the short-interest ratio is currently 0.5 days. Currently, 0.3% of the shares of the company are short sold.
View Exagen's Short Interest.
When is Exagen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our XGN earnings forecast.
How were Exagen's earnings last quarter?: Exagen Inc. (NASDAQ:XGN) announced its earnings results on Monday, March, 18th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.02. The business earned $13.77 million during the quarter, compared to the consensus estimate of $11.43 million. Exagen had a negative trailing twelve-month return on equity of 80.28% and a negative net margin of 45.08%. During the same quarter last year, the business earned ($0.58) earnings per share.

What guidance has Exagen issued on next quarter's earnings?: Exagen issued an update on its FY 2024 earnings guidance on Monday, March, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.0 million-$54.0 million, compared to the consensus revenue estimate of $54.1 million.
What is Ron Rocca's approval rating as Exagen's CEO?: 5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.
When did Exagen IPO?: Exagen (XGN) raised $50 million in an initial public offering (IPO) on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.
Who are Exagen's major shareholders?: Exagen's stock is owned by a number of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (4.56%). Insiders that own company stock include James L L Tullis, John Aballi, Kamal Adawi, Mark Hazeltine and Wendy S Johnson.
View institutional ownership trends.
How do I buy shares of Exagen?: Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Exagen (XGN) Stock Price, News & Analysis

Exagen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Exagen Stock (NASDAQ:XGN)

XGN Stock Price History

XGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

XGN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™